Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Isotis/GenSci

This article was originally published in The Gray Sheet

Executive Summary

Pre-merger licensing pact allows firms to move ahead with platform integration, giving IsoTis access to GenSci technology related to its demineralized bone matrix reverse-phase medium (RPM) carrier system. IsoTis will combine the RPM carrier system with its lead OsSatura synthetic bone substitute technology for dental and maxillofacial reconstruction. A June 3 merger deal is expected to close this fall (1"The Gray Sheet" June 9, 2003, p. 26)...
Advertisement

Related Content

Orthopedic Consolidation Continues: IsoTis Deal Unites Bone Graft Developers
Orthopedic Consolidation Continues: IsoTis Deal Unites Bone Graft Developers
Advertisement
UsernamePublicRestriction

Register

MT018626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel